hotspot -WSS

hotspot

author：entertainment 2025-09-27 12:47:37 - browse：1

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： FDA greenlights medical device to combat bladder issues

WSS

Study: Spinal cord stimulation helps patients with paralysis walk again

How to make over

Virginia high school admissions case could be legal follow

California store owner shot dead in dispute over displaying Pride flag: Police

Peter Hotez and the public health issue of online harassment

People can get long Covid without testing positive for virus: Study

hotspot

hotspot

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Activists slam private health insurers over coverage restrictions

How one medical school became remarkably diverse

Intellia plays down concerns on accidental germline transmission

Bright Health sells Medicare Advantage business to Molina

Vivek Ramaswamy made waves in the debate, much as in biotech

Activists slam private health insurers over coverage restrictions

CDC says it’s too soon to assess risk posed by Covid subvariant

Apple is now the first public company to be valued at $3 trillion

Bright Health sells Medicare Advantage business to Molina

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

FDA greenlights medical device to combat bladder issues

PBMs are inflating the cost of generic drugs. They must be reined in

United colonoscopy coverage change 'may cost lives,' doctors say

Hospital at home shows how to bring innovation to health care

Cancer drug shortages should be causing more outrage

knowledge

hotspot

entertainment

leisure time